Social media of pharmaceutical and medical brand: restrictions and opportunities
Where to move budgets and blogger integrations in 2025–2026 year
Starting from 1 September 2025 year, law No. 72-FZ put an end to the question of whether to work with Meta platforms in Russia: any advertising on Instagram, Facebook, and LinkedIn is banned, with a fine for the company of up to 500 000 ₽ per incident. For a pharmaceutical brand with nationwide reach, this is not a one-time fine, but a systemic risk with every post by a blogger.
In October 2025, advertising budgets were reallocated between platforms, with Telegram receiving a significant share of the budgets, although the exact percentages of view distribution vary depending on the source and research methodology. This is not a future hypothesis, but an already established distribution of attention. Practical conclusion for blogger integrations:
- Telegram — priority for medical channels and doctor ambassadors: the audience here reads thoughtfully, and long formats do not repel
- VK — for the mass OTC segment and promotions through communities, short clips and Widgets work better than longreads
- YouTube — for video expertise, research breakdowns, interviews with doctors, where visual authority is needed
- TikTok — with caveats: requires prior medical content authorization and strict control of trigger words, suitable only for image-based, not product-based formats
A contract with a medical blogger in 2025 year must necessarily include a clause about written consent for using any photos, videos, and patient reviews — even if it's a screenshot of gratitude in comments. Without this consent, the company risks receiving a claim under personal data protection laws, which is a separate risk from advertising legislation and is often overlooked.
What can be published without violating off-label use and promises of results
The main confusion for brands is where the boundary lies between 'educational content' and 'promotion of prescription drugs'. The boundary is actually simple: advertising prescription drugs to the public is prohibited, but content about diseases is not. It is allowed to publish:
- educational materials about the mechanism of the disease, risk factors, diagnosis
- expert opinions of doctors — without linking to a specific trade name
- clinical cases (anonymized, with patient consent)
- recommendations to 'see a doctor' without indicating that your specific drug will solve the problem
The case of a medical center for infusion therapy shows how soft selling works under strict moderation: instead of directly mentioning infusion pumps, the brand used a euphemism 'recovery after a party', a neutral premium visual, and targeted advertising. Result — 490 leads with a budget of $2130, cost per lead $4,3. This is not circumventing the law, but skillful work with formulations where regulators react to words, not the meaning of the service.
Separately, it is worth discussing disclaimers — they are often made as a formal line in small font, which is a direct penalty from the FAS. Requirements are specific: the warning about contraindications must occupy no less than 5% of the advertising material area; in video formats (teleprograms and video services) — no less than 5 seconds and 7% of the frame area. Hiding it in the description under a line is not an option.
Working with comments: where pharmacovigilance begins
This is the section that almost no industry guidelines analyze in detail, and it is precisely here that brands most often fall into a legal trap. A comment under a post is not just a review that can be deleted or ignored. If a user writes about a side effect of a drug, this is a trigger that initiates obligations to a regulator.
Per the European Medicines Agency (EMA) GVP VI guidelines, the company is required to monitor the internet and social networks for reports of adverse reactions and report to the regulator within 15 days of detection. This means that comment moderation in pharma is not about image, but about compliance with pharmacovigilance requirements. The practical scheme for working with comments should include:
- daily screening of comments for keywords («side effect», «feeling bad», «allergy», «did not help»)
- escalation of detected signals to the pharmacovigilance department, not just a moderator's response
- a standard neutral response to the user with a recommendation to consult a doctor and not a public clinical case discussion
- recording the date of detection — regulatory 15 days are counted from this date
Debunking myths in comments — a separate and useful practice: in 2026 year, the FDA sent a warning letter to Pfizer for a Facebook announcement of an oncology drug where exact indications were not stated and information about risks was missing. Even in jurisdictions with formally less stringent regulation, social networks are under enhanced supervision, and this should be kept in mind when responding on behalf of a brand.
Which platform solves which task
Mistake — to manage all social networks with a single template. Each platform has its own audience and its own format of information perception.
| Platform | Main task | Content format | Audience |
|---|---|---|---|
| Telegram | Patient information, myth-busting | longreads, guides, posts with a doctor-expert | thoughtful readers, ERV 1,6 times higher than in VK |
| VK | Mass outreach, working with the OTC segment | clips, carousels, communities with feedback | wide audience 25+ |
| YouTube | Image building, expert authority | interviews, research breakdowns, webinars | patients and doctors seeking depth |
| TikTok | Image tasks covering young audience | short videos without direct promotion of the drug | 18-30 years |
| Working with doctors and B2B-audience | professional publications, clinical data | doctors, buyers |
An important nuance: ERV in Telegram is 1,6 times higher than in VK, and this is not related to the algorithm but to the type of attention — content about 'myth-busting' and step-by-step guides in Telegram engages more strongly than direct posts about the drug precisely because the audience reads slowly and consciously, not scrolling automatically.
Monetizing medical content: where the risks are
Sponsored integrations, affiliate links and paid consultations with doctors through social networks — three monetization formats, each with their own set of risks.
- Sponsored integrations with bloggers-physicians require the marking of "advertisement" and prior verification for compliance with the requirements for disclaimers — 5% of the area or 15% of the video duration
- Affiliate links for purchasing medications — a direct risk of falling under the ban on advertising prescription drugs, if the link leads to a specific product, and not to general information about the disease
- Paid consultations with doctors through social networks require separate legal arrangements: the doctor does not act as a brand representative, but as an independent expert, otherwise the consultation becomes a hidden advertisement for a specific drug
Any monetization in the pharmaceutical industry must be legally verified before publication, not after a user complaint — post-factum fines cannot be stopped.
The legal framework that most brands stumble upon
At the core of all restrictions is the law on advertising and the aforementioned 72-FZ. The first regulates the content of advertising messages (prohibition on guarantees of results, mandatory disclaimers, restrictions on advertising prescription drugs to the public). The second, as of September 2025, closed an entire advertising channel — Meta platforms — for all Russian companies, including pharma. Platforms that remain accessible — Meta for organic publications formally still exists, but advertising on it is prohibited — require prior authorization of medical content: this includes LinkedIn and TikTok, where the moderation algorithm automatically blocks posts with medical terminology without prior account approval.
Understanding this base is not a formality for a lawyer, but a working tool for a content manager: knowing what is allowed and what is not allowed at the legal level, it is easier to build a funnel from an educational post to a consultation with a doctor, without risking a fine at every step.
Where to move budgets and blogger integrations in 2025–2026 year
Starting from 1 September 2025 year, law No. 72-FZ put an end to the question of whether to work with Meta platforms in Russia: any advertising on Instagram, Facebook, and LinkedIn is banned, with a fine for the company of up to 500 000 ₽ per incident. For a pharmaceutical brand with nationwide reach, this is not a one-time fine, but a systemic risk with every post by a blogger.
In October 2025, advertising budgets were reallocated between platforms, with Telegram receiving a significant share of the budgets, although the exact percentages of view distribution vary depending on the source and research methodology. This is not a future hypothesis, but an already established distribution of attention. Practical conclusion for blogger integrations:
- Telegram — priority for medical channels and doctor ambassadors: the audience here reads thoughtfully, and long formats do not repel
- VK — for the mass OTC segment and promotions through communities, short clips and Widgets work better than longreads
- YouTube — for video expertise, research breakdowns, interviews with doctors, where visual authority is needed
- TikTok — with caveats: requires prior medical content authorization and strict control of trigger words, suitable only for image-based, not product-based formats
A contract with a medical blogger in 2025 year must necessarily include a clause about written consent for using any photos, videos, and patient reviews — even if it's a screenshot of gratitude in comments. Without this consent, the company risks receiving a claim under personal data protection laws, which is a separate risk from advertising legislation and is often overlooked.
What can be published without violating off-label use and promises of results
The main confusion for brands is where the boundary lies between 'educational content' and 'promotion of prescription drugs'. The boundary is actually simple: advertising prescription drugs to the public is prohibited, but content about diseases is not. It is allowed to publish:
- educational materials about the mechanism of the disease, risk factors, diagnosis
- expert opinions of doctors — without linking to a specific trade name
- clinical cases (anonymized, with patient consent)
- recommendations to 'see a doctor' without indicating that your specific drug will solve the problem
The case of a medical center for infusion therapy shows how soft selling works under strict moderation: instead of directly mentioning infusion pumps, the brand used a euphemism 'recovery after a party', a neutral premium visual, and targeted advertising. Result — 490 leads with a budget of $2130, cost per lead $4,3. This is not circumventing the law, but skillful work with formulations where regulators react to words, not the meaning of the service.
Separately, it is worth discussing disclaimers — they are often made as a formal line in small font, which is a direct penalty from the FAS. Requirements are specific: the warning about contraindications must occupy no less than 5% of the advertising material area; in video formats (teleprograms and video services) — no less than 5 seconds and 7% of the frame area. Hiding it in the description under a line is not an option.
Working with comments: where pharmacovigilance begins
This is the section that almost no industry guidelines analyze in detail, and it is precisely here that brands most often fall into a legal trap. A comment under a post is not just a review that can be deleted or ignored. If a user writes about a side effect of a drug, this is a trigger that initiates obligations to a regulator.
Per the European Medicines Agency (EMA) GVP VI guidelines, the company is required to monitor the internet and social networks for reports of adverse reactions and report to the regulator within 15 days of detection. This means that comment moderation in pharma is not about image, but about compliance with pharmacovigilance requirements. The practical scheme for working with comments should include:
- daily screening of comments for keywords («side effect», «feeling bad», «allergy», «did not help»)
- escalation of detected signals to the pharmacovigilance department, not just a moderator's response
- a standard neutral response to the user with a recommendation to consult a doctor and not a public clinical case discussion
- recording the date of detection — regulatory 15 days are counted from this date
Debunking myths in comments — a separate and useful practice: in 2026 year, the FDA sent a warning letter to Pfizer for a Facebook announcement of an oncology drug where exact indications were not stated and information about risks was missing. Even in jurisdictions with formally less stringent regulation, social networks are under enhanced supervision, and this should be kept in mind when responding on behalf of a brand.
Which platform solves which task
Mistake — to manage all social networks with a single template. Each platform has its own audience and its own format of information perception.
| Platform | Main task | Content format | Audience |
|---|---|---|---|
| Telegram | Patient information, myth-busting | longreads, guides, posts with a doctor-expert | thoughtful readers, ERV 1,6 times higher than in VK |
| VK | Mass outreach, working with the OTC segment | clips, carousels, communities with feedback | wide audience 25+ |
| YouTube | Image building, expert authority | interviews, research breakdowns, webinars | patients and doctors seeking depth |
| TikTok | Image tasks covering young audience | short videos without direct promotion of the drug | 18-30 years |
| Working with doctors and B2B-audience | professional publications, clinical data | doctors, buyers |
An important nuance: ERV in Telegram is 1,6 times higher than in VK, and this is not related to the algorithm but to the type of attention — content about 'myth-busting' and step-by-step guides in Telegram engages more strongly than direct posts about the drug precisely because the audience reads slowly and consciously, not scrolling automatically.
Monetizing medical content: where the risks are
Sponsored integrations, affiliate links and paid consultations with doctors through social networks — three monetization formats, each with their own set of risks.
- Sponsored integrations with bloggers-physicians require the marking of "advertisement" and prior verification for compliance with the requirements for disclaimers — 5% of the area or 15% of the video duration
- Affiliate links for purchasing medications — a direct risk of falling under the ban on advertising prescription drugs, if the link leads to a specific product, and not to general information about the disease
- Paid consultations with doctors through social networks require separate legal arrangements: the doctor does not act as a brand representative, but as an independent expert, otherwise the consultation becomes a hidden advertisement for a specific drug
Any monetization in the pharmaceutical industry must be legally verified before publication, not after a user complaint — post-factum fines cannot be stopped.
The legal framework that most brands stumble upon
At the core of all restrictions is the law on advertising and the aforementioned 72-FZ. The first regulates the content of advertising messages (prohibition on guarantees of results, mandatory disclaimers, restrictions on advertising prescription drugs to the public). The second, as of September 2025, closed an entire advertising channel — Meta platforms — for all Russian companies, including pharma. Platforms that remain accessible — Meta for organic publications formally still exists, but advertising on it is prohibited — require prior authorization of medical content: this includes LinkedIn and TikTok, where the moderation algorithm automatically blocks posts with medical terminology without prior account approval.
Understanding this base is not a formality for a lawyer, but a working tool for a content manager: knowing what is allowed and what is not allowed at the legal level, it is easier to build a funnel from an educational post to a consultation with a doctor, without risking a fine at every step.
Recent articles
MegaFon, BMW, VTB and more 240+ companies. See how it looks in the showcase reel:
Our branding agency is approached to order:
Branding agency services
